Compare WH & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WH | KRYS |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.3B |
| IPO Year | N/A | 2017 |
| Metric | WH | KRYS |
|---|---|---|
| Price | $73.88 | $217.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 9 |
| Target Price | $95.13 | ★ $214.22 |
| AVG Volume (30 Days) | ★ 1.1M | 265.4K |
| Earning Date | 10-22-2025 | 11-03-2025 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | 38.00 | ★ 275.72 |
| EPS | 4.33 | ★ 6.66 |
| Revenue | ★ $1,436,000,000.00 | $373,164,000.00 |
| Revenue This Year | $5.20 | $36.14 |
| Revenue Next Year | $5.75 | $41.80 |
| P/E Ratio | ★ $17.09 | $32.68 |
| Revenue Growth | 3.83 | ★ 54.51 |
| 52 Week Low | $69.21 | $122.80 |
| 52 Week High | $113.07 | $221.84 |
| Indicator | WH | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 50.91 | 69.95 |
| Support Level | $71.92 | $212.75 |
| Resistance Level | $75.13 | $221.84 |
| Average True Range (ATR) | 1.81 | 6.83 |
| MACD | 0.50 | 0.06 |
| Stochastic Oscillator | 78.89 | 82.60 |
As of June 30, 2025, Wyndham Hotels & Resorts operates 846,700 rooms across more than 20 brands predominantly in the economy and midscale segments. Super 8 is the largest brand, representing around 18% of all rooms, with Days Inn (13%) and Ramada (14%) the next two largest brands, as of the end of 2024. During the past several years, the company has expanded its extended stay/lifestyle brands, which appeal to travelers seeking to experience the local culture of a given location. The company closed its La Quinta acquisition in the second quarter of 2018, adding around 90,000 rooms at the time the deal closed. Wyndham launched a new extended stay economy scale segment concept, ECHO, in the spring of 2022. The United States represents 56% of total rooms, as of the end of 2024.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.